Skip to main
BEAT

HeartBeam (BEAT) Stock Forecast & Price Target

HeartBeam (BEAT) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

HeartBeam is a medical technology company that has recently developed a proprietary technology platform that allows for 12-lead ECG readings to be taken remotely, rather than solely in a clinical setting. With a growing market for remote and digitally-enabled care models, HeartBeam has the potential to disrupt the $2B mobile cardiac telemetry (MCT) segment with their extended-wear patch, offering capabilities for ischemia detection. However, there are risks to consider such as competition from established monitoring companies and potential capital requirements for commercialization and market expansion. With upcoming milestones including clinical trials for heart attack detection and the limited commercial launch of their technology, HeartBeam seems to be well-positioned for growth.

Bears say

HeartBeam is a medical technology company with a novel ambulatory ECG technology that aims to replicate diagnostic-grade 12-lead ECGs using a compact patient-operated device. Despite its FDA clearance and potential multi-billion-dollar revenue opportunity, the company may face challenges in commercial adoption due to slower physician integration and market development. Additionally, any limitations in technology or product performance could hinder acceptance and ultimately impact the company's competitive positioning.

HeartBeam (BEAT) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of HeartBeam and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About HeartBeam (BEAT) Forecast

Analysts have given HeartBeam (BEAT) a Strong Buy based on their latest research and market trends.

According to 5 analysts, HeartBeam (BEAT) has a Strong Buy consensus rating as of Aug 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.70, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.70, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

HeartBeam (BEAT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.